Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation
Naunyn-Schmiedeberg's Archives of Pharmacology · 07.02.2023
DOI: 10.1007/s00210-023-02409-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 07.02.2023. Verfasst von Jiaxin Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, No.158…. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Diabetic Cardiomyopathies, Heart Failure. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dilated cardiomyopathy (DCM) is the major cause of heart failure and has a poor prognosis. The accumulating evidence points to an essential role of the inflammatory component in the process of DCM. Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are widely used to treat heart failure patients due to their cardiac benefits. However, their role in DCM remains unclear. We used the doxorubicin (Dox)-induced DCM model for our study. The SGLT2 inhibitor dapagliflozin (Dapa) improved cardiac function in mice treated with doxorubicin and attenuated the activation of the nucleotide-binding oligomerization domain-like receptor family protein 3 (NLRP3) inflammasome pathway and the expression of inflammatory factors. In addition, dapagliflozin suppresses NLRP3 activation by decreasing p38-dependent toll-like receptor 4 (TLR4) expression. In our study, dagliflozin improves cardiac function in DCM by inhibiting the activity of the NLRP3 inflammasome. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, No.158 Wuyang Avenue, Enshi, 445000, Hubei, China.
- Department of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- Department of Cardiology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Zhongshan Road, Nanjing, 210008, China.
- Department of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi, Hubei, China.
- Surgical Division IIIThe Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, Hubei, China.
- Department of Cardiology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Zhongshan Road, Nanjing, 210008, China. Xubiao-nju@outlook.com.
Zitieren
APA
Hu, J., Xu, J., Tan, X., Li, D., Yao, D., Xu, B., & Lei, Y. (2023). Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02409-5
Vancouver
Hu J, Xu J, Tan X, Li D, Yao D, Xu B, et al. Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023. doi:10.1007/s00210-023-02409-5
BibTeX
@article{Hu2023,
author = {Hu, Jiaxin and Xu, Jiamin and Tan, Xi and Li, Dong and Yao, Dejiang and Xu, Biao and Lei, Yuhua},
title = {Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2023},
doi = {10.1007/s00210-023-02409-5}
}
EUVIMED